Pipeline Review on Hepatitis C Virus Envelope Protein E2 - H2 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020" drug pipelines have been added to ResearchAndMarkets.com's offering.

According to the recently published report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 9 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.

Hepatitis C Virus Envelope Protein E2 - E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.

The report 'Hepatitis C Virus Envelope Protein E2 - Pipeline Review, H2 2020' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C.

Scope

• The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2
• The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects
• The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

1. Introduction

2. Hepatitis C Virus Envelope Protein E2 - Overview

3. Hepatitis C Virus Envelope Protein E2 - Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes

4. Hepatitis C Virus Envelope Protein E2 - Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

5. Hepatitis C Virus Envelope Protein E2 - Companies Involved in Therapeutics Development

• Ennaid Therapeutics LLC
• Integrated BioTherapeutics Inc
• Toray Industries Inc

6. Hepatitis C Virus Envelope Protein E2 - Drug Profiles

7. Hepatitis C Virus Envelope Protein E2 - Discontinued Products

8. Hepatitis C Virus Envelope Protein E2 - Product Development Milestones

• Featured News & Press Releases
• Jun 10, 2013: IBT and Stanford Awarded STTR

9. Appendix

• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact
• Disclaimer

Companies Mentioned

• Ennaid Therapeutics LLC
• Integrated BioTherapeutics Inc
• Toray Industries Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ytfnhu